Scientific Opinion on the substantiation of health claims related to vitamin D and normal function of the immune system and inflammatory response (ID 154, 159), maintenance of normal muscle function (ID 155) and maintenance of normal cardiovascular function (ID 159) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

EFSA Journal

Volumn 8, Issue 2, 2010, Pages

[No Author Info available]

Author keywords

cardiovascular function; health claims; immune system; inflammatory response; muscle function; Vitamin D

Indexed keywords

EID: 85020927521     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2010.1468     Document Type: Note

References (19)

1. Armas LAG, Hollis BW and Heaney RP, 2004. Vitamin D2 is less effective than vitamin D3 in humans. Journal of Clinical Endocrinology & Metabolism, 89, 5387– 5391.
2. Bikle D, 2009. Nonclassic actions of vitamin D. Journal of Clinical Endocrinology & Metabolism, 94, 26–34.
3. Cantorna MT, Yu S and Bruce D, 2008. The paradoxical effects of vitamin D on type 1 mediated immunity. Molecular Aspects of Medicine, 29, 369–375.
4. CEDAP 1997. Avis de la commission interministérielle d'étude des produits destinés à une alimentation particulière (CEDAP) en date du 18 décembre 1996 sur les recommandations relatives au caractère non trompeur des seuils des allégations nutritionnelles fonctionnelles. BOCCRF (Bulletin Officiel de la Concurrence, de la Consommation et de la Répression des fraudes) du 7 octobre 1997.
5. Ceglia L, 2008. Vitamin D and skeletal muscle tissue and function. Molecular Aspects of Medicine, 29, 407–414.
6. Cohen-Lahay M, Douvdevani A, Chaimovitz C and Shany S, 2007. The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. Journal of Steroid Biochemistry and Molecular Biology, 103, 558–562.
7. Cotler R, Moreines J, and Ellenogen L, 2008. Potential benefits for the use of vitamin and mineral supplements, in Handbook of Nutrition and Food, 2nd Edition, ed. By Berdanier C, Dwyer J, Feldman B, CRC Press, 193–219.
8. JHCI (Joint Health Claims Initiative), 2003. Final Technical Report A List of Well Established Nutrient Function Statements.
9. Khazai N, Judd S and Tangpricha V, 2008. Calcium and vitamin D: skeletal and extraskeletal health. Current Rheumatology Reports, 10, 110–117.
10. NFA (Finnish National Food Authority), 2002. Terveysväitteiden valvontaopas. Control guides number 3/2002.
11. NHPD (Natural Health Products Directorate), 2009. Canadian Food and Drug Regulations C.R.C., c. 870. Health claims (Sections B.01.600-B.01.603).
12. Norman AW and Henry HH, 2007. Vitamin D, in Present Knowledge in Nutrition, ed. Bowman BA and Russell RM, Intl Life Sciences Inst; 9th edition, 198–210.
13. ODAIOUs, 1995. Ordonnance du Conseil Fédéral Suisse du Mars 1995 sur le denrées alimentaires et les objets usuels.
14. Patel S, Farragher T, Berry J, Bunn D, Sliman A and Symmons D, 2007. Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheumatisms, 56, 2143–2149.
15. SCF (Scientific Committee on Food), 2002. Opinion on the Tolerable Upper Intake Level of Vitamin D.
16. Schott GD and Wills MR, 1976. Muscle weakness in osteomalacia. Lancet, 1, 626–629.
17. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T and Nishizawa Y, 2004. Lower risk for cardiovascular mortality in oral 1α-hydroxy vitamin D3 users in a haemodialysis population. Nephrology Dialysis Transplantation, 19, 179–184.
18. SNF (Swedish Nutrition Foundation), 2004. Health claims in the labelling and marketing of food products. The food sector's code of practice.
19. Sorensen O, Lund B, Saltin B, Andersen R, Hjorth L, Melsen F and Mosekilde L, 1979. Myopathy in bone loss of ageing: improvement by treatment with 1 alpha-hydroxycholecalciferol and calcium. Clinical Science, 56, 157–161.